Table 2. Summary of clinicopathological findings of case reports of primary neuroendocrine breast carcinoma published since 2000.
| Author/Year (Ref.) |
Age | Size (mm) | Clinical Findings | Imaging Findings Mammogram/US | Pathological Immunohistochemical Findings |
Treatment | Follow-up | Outcome |
|---|---|---|---|---|---|---|---|---|
| SALEMIS/2020 | 50 | 30 | None | Architectural distortion, Calcifications | ER+, PR+, HER2- | MT+ALND | 44 | AWD |
| (present case) | Hypoechoic mass. Irregular margins | Syn+, CgA-, N+ | Chemo, RT, ET | |||||
| VALENTE/2020 | 69 | 15 | Palpable mass, nipple, | Nodule with calcifications | ER-, PR-, HER2- | BCS+ALND | 96 | AWRD |
| (39) | areolar erosions | CgA+, N+ | Chemo, RT, ET | |||||
| Nodule with irregular margins and posterior shadowing | Concomitant invasive lobular carcinoma | |||||||
| PULAT/2019 | 73 | 40 | Pain, swelling, skin | Macrolobular mass | ER+, PR+, HER2- | MT+ALND | 48 | AWD |
| (40) | changes | Irregular, hypoechoic mass | N- | ET | ||||
| TREMELLING/2017 | 65 | 50 | Palpable mass | Irregular mass with increased vascularity | ER-, PR-, HER2-, | Chemo, RT | 3 | AWD |
| (41) | Syn+, CgA+ | |||||||
| N+ | ||||||||
| SOE/2017 | 57 | 40 | Palpable mass | Oval, lobulated | ER+,PR+, Syn+,CgA+ | BCS+Chemo | 18 | AWRD |
| (42) | dense with mass calcifications | |||||||
| Hypoechoic lobulated mass with marked posterior enhancement | ||||||||
| BERGSTROM/2017 | 53 | 80 | Palpable mass | Irregular mass | ER+, PR-, HER2- | Chemo | N/A | N/A |
| (43) | Syn+, CgA+ | |||||||
| VATS/2017 | 32 | 60 | Palpable mass | BIRADS-5 | ER+, PR+, HER2+ | Chemo, RT | 12 | AWRD |
| (44) | Syn+, CgA+, N+ | |||||||
| MEKIAROVA/2016 | 42 | 32 | Palpable mass | Circumscribed mass with calcifications | ER-, PR-, HER2-, | BCS+SLNB | 36 | AWD |
| (45) | Hypoechoic mass with enhancement | Syn+, CgA+ | ||||||
| MARINOVA/2016 | 42 | 35 | None | Distinctive mass with microcalcifications | ER+, PR+, HER2-, N+ | BT+ALND | 12 | AWD |
| (46) | Chemo, RT, ET | |||||||
| YOSHIMURA/2015 | 34 | N/A | Palpable mass | Microlobulated, hyperdense mass | ER+, PR+, | MT+ALND. | 48 | AWD |
| (47) | HER2-, N+ | Refused | ||||||
| adjuvant | ||||||||
| treatment | ||||||||
| WRONSKI/2015 | 45 | 22 | None | N/A | ER+, PR+, HER2- | BCS+ALND | N/A | N/A |
| (48) | Syn+, CgA+ , N+ | |||||||
| TATO-VARELA/2015 | 62 | 20 | Palpable mass | Increased trabeculation | ER+, PR+, | MT+ALND | N/A | AWD |
| (21) | HER2- | Chemo, RT | ||||||
| Syn+, CgA+, N+ | ||||||||
| WEI/2014 | 43 | 83 | Palpable mass | Irregular mass | ER+, PR-, HER2+ | MT+ALND | N/A | N/A |
| (49) | Lobulated lump | Syn+, N+ | Chemo | |||||
| Hypoechoic mass | ||||||||
| PANJVANI/2015 | 70 | 25 | Breast swelling | Hypoechoic mass with increased vascularity | Syn+ | MT+ALND | N/A | N/A |
| (50) | ||||||||
| LEE/2015 | 48 | 24 | Breast enlargement, | Diffuse skin thickening | ER+, PR+, HER2- | Chemo, | N/A | AWRD |
| (51) | eythema | Hypoechoic irregular mass | Syn+, N+ | RT, ET | ||||
| JANOSKY/2015 | 34 | 43 | Palpable mass | Irregular mass with calcifications | ER-, PR-, HER2- | Chemo, MT, RT | N/A | AWRD |
| (52) | CgA+, Syn+ | |||||||
| ALVA/2015 | 53 | 50 | Palpable mass | Irregular lump | ER-, PR-, HER2- | MT, Chemo | N/A | AWD |
| (53) | CgA+, Syn+, N- | |||||||
| VALENTIM/2014 | 75 | 19 | None | Ovoid, well defined mass | CgA+, Syn+ | BCS | N/A | N/A |
| (54) | Hypoechoic irregular mass without posterior enhancement | |||||||
| PAGANO/2014 | 51 | 35 | Palpable lump | Irregular mass | ER+, PR+, HER2- | MT+ALND | 126 | AWD |
| (55) | CgA+, Syn+, N+ | Chemo, ET | ||||||
| BOZKURT/2014 | 75 | 31 | Palpable mass | Spiculated Mass | ER+, PR+, HER2- | MT,Chemo, RT | N/A | AWD |
| (56) | Hypoechoic mass with regular borders | CgA+, Syn+, | ||||||
| LINGAPPA/2014 | 80 | 100 | Palpable mass | Well-defined mass | CgA+, N+ | MT+ALND | N/A | N/A |
| (57) | Chemo | |||||||
| TAJIMA/2013 | 78 | 20 | None | N/A | ER+, PR+, HER2- | BCS+ALND, | N/A | N/A |
| (58) | CgA+, Syn+, N+ | ET | ||||||
| MURTHY/2013 | 34 | 25 | Palpable mass | Ill defined-mass | ER+, PR+, HER2- | MT+ALND | 6 | AWD |
| (59) | CgA+, Syn+, N- | Chemo, TR,ET | ||||||
| HANNA/2013 | 60 | 20 | Axillary mass | None | ER+, PR+, HER2- | BCS+ALND | N/A | N/A |
| (60) | Enlarged axillary node | Chemo | ||||||
| ANGARITA/2013 | 51 | 32 | Breast lump | Spiculated mass with calcifications | ER+, PR-, | Chemo, RT, MT+ALND, | 13 | AWRD |
| (20) | HER2- | ET | ||||||
| CgA+, Syn+, | ||||||||
| WATROWSKI/2012 | 56 | 17 | Palpable mass | Hypoechoic mass with angular margins and | ER+, PR-, | BCS, Chemo, | 15 | AWD |
| (61) | posterior shadowing | HER2-, Syn+ | RT, ET | |||||
| N- | ||||||||
| SANGUINETTI/2012 | 63 | 65 | Bulky mass, skin | Mass with suspicious characteristics | ER+, PR+, | Chemo, MT+ALND, ET | 6 | AWRD |
| (62) | changes | HER2-, Syn+ | ||||||
| CgA+, N+ | ||||||||
| PSOMA/2012 | 46 | 80 | Palpable mass | Asymetric Hyperdense Microlobulated Area | CgA+, Syn+ | MT+ALND, | 6 | AWD |
| (63) | Hypoechoic irregular mass with posterior enhancement | Paget disease. | RT | |||||
| NAWAWI/2012 | 22 | 24 | Palpable mass | Hypoechoic mass | N/A | Chemo | N/A | Died |
| (64) | ||||||||
| GRACA/2012 | 83 | 85 left | Palpable lump | Nodule with Benign characteristics. | ER+, PR+, Syn+ | BCS+SLNB | N/A | AWD |
| (65) | Heterogeneous benign nodule | ET | ||||||
| ZHANG/2011 | 29 | 20 right | Bilateral Nipple | Bilateral Suspicious lesions | ER+, PR+, | Bilateral BCS+ Axillary sampling, Chemo | N/A | N/A |
| (66) | discharge | HER2-, Syn+ | ||||||
| N- | ||||||||
| GHANEM/2011 | 64 | 80 | Palpable mass | Suspicious characteristics | ER+, PR+, | Chemo, MT+ALND, ET | 6 | AWRD |
| (67) | HER2-, Syn+ | |||||||
| N+ |
CS: case series, RR: retrospective review, LR: literature review, ER: estrogen receptors, PR: progesterone receptors, Syn: synaptophysin, CgA: chromogranin A, MT: mastectomy, BCS: breast conserving surgery, SLNB: sentinel lymph node biopsy, ALND: axillary lymph node dissection, N: nodes, Chemo: chemotherapy, RT: radiation therapy, ET: endocrine therapy, AWD: alive without disease, AWRD: alive with recurrent disease, N/A: not available